All In Biotech

Drug Trial Radar · NCT07639931

Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application

Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 3,035 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

3,035

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 20, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Tibet Autonomous Region People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.

Conditions

  • Severe High Altitude Pulmonary Edema
  • Severe High Altitude Cerebral Edema

Interventions

  • Multicenter study of HAPE:CPAP or BiPAP GroupDevice

    Traditional treatment plus CPAP or BiPAP

  • Multicenter study of HAPE group:NO GroupDrug

    Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)

  • Protocol for Proteomics and Peptidomics Study of HAPE:Case GroupOther

    40 patients clinically diagnosed with HAPE. Peripheral venous blood samples were collected during the acute onset stage and prior to any effective intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HAPE:RecoveryTime frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
  2. HACE :recoveryTime frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
  3. DeathTime frame: From admission to discharge, or all-cause mortality within 30 days and 90 days after discharge.
  4. Length of hospital stayTime frame: The total duration from the first day of hospitalization to recovery and discharge, assessed up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xizang Autonomous Region People's Hospital

    Lhasa, Tibet, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.